Overview A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome Status: Recruiting Trial end date: 2026-04-01 Target enrollment: Participant gender: Summary A Phase 1b/2a, first-in-disease, open-label, multiple-ascending dose exploratory study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamic biomarker responses associated with CRN04894 (an adrenocorticotropic hormone [ACTH] receptor antagonist) in participants with ACTH-dependent Cushing's syndrome (Cushing's disease or Ectopic ACTH Syndrome [EAS]) Phase: Phase 1/Phase 2 Details Lead Sponsor: Crinetics Pharmaceuticals Inc.